FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W8391018> ?p ?o ?g. }

• W8391018 endingPage "6" @default.
• W8391018 startingPage "571" @default.
• W8391018 abstract "To evaluate the effectiveness and safety of combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) regimen on the patients with high-risk gestational trophoblastic neoplasia (GTN).Forty-two patients with high-risk GTN admitted in Sichuan Cancer Hospital between Jan.1997 and Oct. 2011 were analyzed retrospectively. The International Federation of Gynecology and Obstetrics (FIGO) prognostic score of all patients was more than 7. The mean age of patients was 30.2 years (range 20 - 49 years). All patients were treated with more than two cycles BEP regimen and followed up to the patients' death or at the end of Feb.2012. The clinical response, toxicity and the occurrence of secondary tumors were investigated.Forty-two high-risk GTN patients received the total of 251 courses of the BEP regimen, the average number of courses for each patient was 6.0 courses. Thirty-seven patients achieved complete remission and 5 patients showed drug-resistant. The total complete remission rate of BEP regimen was 88% (37/42). Among the complete remission patients, the total courses of BEP regimen of cases getting normal serum β-hCG level was 129 courses (average 3.5 courses), and the total courses of cases achieving complete remission was 227 courses (average 6.1 courses). Among the 37 complete remission patients, 31 cases were treated with BEP regimen chemotherapy alone, 4 patients with BEP regimen chemotherapy combined with surgical treatment (1 case had no cancer after surgery) and 2 cases with BEP regimen chemotherapy combined with radiation therapy. Therefore, the complete remission rate of BEP regimen chemotherapy alone was 74% (31/42). There were 5 patients who showed drug-resistance after 24 courses of BEP regimen chemotherapy (average 4.8 courses), then received etoposide, methotrexate and dactinomycin (EMA)/cyclophosphamide and vincristine sulfate (CO) regimen chemotherapy after drug-resistance, 2 cases combined with radiation therapy, 1 case combined with surgical treatment. Ultimately, 4 cases achieved complete remission, 1 case died of cancer. The major toxicities of BEP regimen were included bone marrow suppression, digestive tract side effect and alopecic, followed by mild peripheral neuritis and abnormal liver function, rare cases of mild pulmonary toxicity. There were no severe anaphylaxis and obvious impairment of cardiac, liver, pulmonary and kidney function, except 1 patient (49 years old) had grade IV bone marrow suppression and pulmonary fibrosis worsened after chemotherapy. The bone marrow suppression was mainly I-III degree neutropenia, and Incidence rate was 66.5% (167/251). All the survival patients without secondary tumor.For young high-risk GTN patients, BEP regimen chemotherapy may be safe and effective." @default.
• W8391018 created "2016-06-24" @default.
• W8391018 creator A5017116648 @default.
• W8391018 creator A5082569423 @default.
• W8391018 date "2012-08-01" @default.
• W8391018 modified "2023-09-23" @default.
• W8391018 title "[Therapeutic evaluation of cisplatin, etoposide, and bleomycin chemotherapy regimen in high-risk gestational trophoblastic neoplasia]." @default.
• W8391018 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23141175" @default.
• W8391018 hasPublicationYear "2012" @default.
• W8391018 type Work @default.
• W8391018 sameAs 8391018 @default.
• W8391018 citedByCount "0" @default.
• W8391018 crossrefType "journal-article" @default.
• W8391018 hasAuthorship W8391018A5017116648 @default.
• W8391018 hasAuthorship W8391018A5082569423 @default.
• W8391018 hasConcept C126322002 @default.
• W8391018 hasConcept C141071460 @default.
• W8391018 hasConcept C2776232574 @default.
• W8391018 hasConcept C2776694085 @default.
• W8391018 hasConcept C2778119113 @default.
• W8391018 hasConcept C2778239845 @default.
• W8391018 hasConcept C2781413609 @default.
• W8391018 hasConcept C71924100 @default.
• W8391018 hasConceptScore W8391018C126322002 @default.
• W8391018 hasConceptScore W8391018C141071460 @default.
• W8391018 hasConceptScore W8391018C2776232574 @default.
• W8391018 hasConceptScore W8391018C2776694085 @default.
• W8391018 hasConceptScore W8391018C2778119113 @default.
• W8391018 hasConceptScore W8391018C2778239845 @default.
• W8391018 hasConceptScore W8391018C2781413609 @default.
• W8391018 hasConceptScore W8391018C71924100 @default.
• W8391018 hasIssue "8" @default.
• W8391018 hasLocation W83910181 @default.
• W8391018 hasOpenAccess W8391018 @default.
• W8391018 hasPrimaryLocation W83910181 @default.
• W8391018 hasRelatedWork W1966513127 @default.
• W8391018 hasRelatedWork W1996533072 @default.
• W8391018 hasRelatedWork W2077980843 @default.
• W8391018 hasRelatedWork W2091883565 @default.
• W8391018 hasRelatedWork W2105229494 @default.
• W8391018 hasRelatedWork W2381985526 @default.
• W8391018 hasRelatedWork W2417697013 @default.
• W8391018 hasRelatedWork W2922163800 @default.
• W8391018 hasRelatedWork W3199647676 @default.
• W8391018 hasRelatedWork W2519687743 @default.
• W8391018 hasVolume "47" @default.
• W8391018 isParatext "false" @default.
• W8391018 isRetracted "false" @default.
• W8391018 magId "8391018" @default.
• W8391018 workType "article" @default.